Amylyx completes acquisition of Avexitide from Eiger for $35.1M

Amylyx Pharmaceuticals, Inc.

Acquired Avexitide from Eiger BioPharmaceuticals for $35.1 million plus cure costs and assumed liabilities.
Sale approved by U.S. Bankruptcy Court for Northern District of Texas on June 26, 2024; closed July 9, 2024.
Amylyx will handle development, manufacture, and commercialization of Avexitide post-closing.
Transaction follows Asset Purchase Agreement dated June 21, 2024, as previously disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.